Directorio independiente

CENEIT Oncológicos

Ciudad de México. Esta página agrupa registros donde ClinicalTrials.gov publica nombres de sede que coinciden con este centro dentro de las condiciones que monitoreamos.

Perfil informativo no verificado por el centro

Construido a partir de registros públicos; no implica afiliación.

Sin afiliación: BiomedicalResearch.mx no afirma representar a este centro y no garantiza que este listado sea completo. Confirma siempre nombre, dirección, contacto y estatus en el registro oficial.

Variantes de nombre encontradas

  • CENEIT Oncologicos
  • CENEIT Oncologicos ( Site 0706)

Estudios detectados

ReclutandoNCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT05646862

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Fase 3Hoffmann-La Roche
Ver ficha informativa
ReclutandoNCT05894239

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT06926868

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Fase 2 / Fase 3Bristol-Myers Squibb
Ver ficha informativa
ReclutandoNCT07368998

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Fase 2Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Fase 2 / Fase 3Bristol-Myers Squibb
Ver registro oficial ↗